It is most appropriate to take several courses of Midostaurin

Midostaurin is a multi-target tyrosine kinase inhibitor that is widely used worldwide to treat certain types of acute myeloid leukemia (AML) and the rare disease mastocytosis (MCL). The most representative application of this drug is to inhibit the proliferation of malignant cells and delay the progression of the disease by blocking key signaling pathways of tumor cells in AML patients carrying FLT3 mutations. It is also one of the first targeted drugs approved by international drug regulatory agencies for FLT3-positive AML, providing a practical model for the development of precision medicine.

In patients with leukemia, it is usually used as a combination drug for induction chemotherapy and consolidation therapy, that is, midostaurin is added to the traditional drugs such as cytarabine and daunorubicin to form a combination regimen. At this stage, it is generally recommended to take it continuously for a certain number of days, and then evaluate the efficacy in conjunction with the chemotherapy cycle. After the consolidation period, doctors will develop a follow-up treatment plan based on whether the patient is ready to receive a hematopoietic stem cell transplant or enter the maintenance treatment phase. In some patients, if the bone marrow response is good and there are no serious side effects, midostaurin can also be used as an auxiliary option for maintenance therapy and can be used for several months to reduce the risk of recurrence.

In the treatment of mastocytosis, midostaurin is usually used as a long-term treatment drug with a longer cycle, and may even need to be taken continuously to control multi-system damage caused by abnormal proliferation of mast cells. However, even for chronic use, patients still need to closely monitor blood routine, liver and kidney function and other indicators to ensure the safety of the drug.

It needs to be made clear that the setting of midostaurin treatment course is highly individualized and is affected by factors such as the patient's age, physical status, genotype, comorbidities, and drug tolerance. The length of treatment cannot simply be based on "several courses of treatment" and must be dynamically adjusted by the doctor according to the patient's condition.

Reference materials:https://go.drugbank.com/drugs/DB06595